Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

581 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A dose escalation trial of adjuvant cyclophosphamide and epirubicin in combination with 5-fluorouracil using G-CSF support for premenopausal women with breast cancer involving four or more positive nodes.
Findlay B, Tonkin K, Crump M, Norris B, Trudeau M, Blackstein M, Burnell M, Skillings J, Bowman D, Walde D, Levine M, Pritchard KI, Palmer MJ, Tu D, Shepherd L. Findlay B, et al. Among authors: shepherd l. Ann Oncol. 2007 Oct;18(10):1646-51. doi: 10.1093/annonc/mdm277. Epub 2007 Aug 22. Ann Oncol. 2007. PMID: 17716984 Free article. Clinical Trial.
A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada--Clinical Trials Group Trial, MA.12).
Bramwell VHC, Pritchard KI, Tu D, Tonkin K, Vachhrajani H, Vandenberg TA, Robert J, Arnold A, O'Reilly SE, Graham B, Shepherd L. Bramwell VHC, et al. Among authors: shepherd l. Ann Oncol. 2010 Feb;21(2):283-290. doi: 10.1093/annonc/mdp326. Epub 2009 Jul 23. Ann Oncol. 2010. PMID: 19628570 Free PMC article. Clinical Trial.
Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. Breast Cancer Site Group.
Pritchard KI, Paterson AH, Fine S, Paul NA, Zee B, Shepherd LE, Abu-Zahra H, Ragaz J, Knowling M, Levine MN, Verma S, Perrault D, Walde PL, Bramwell VH, Poljicak M, Boyd N, Warr D, Norris BD, Bowman D, Armitage GR, Weizel H, Buckman RA. Pritchard KI, et al. Among authors: shepherd le. J Clin Oncol. 1997 Jun;15(6):2302-11. doi: 10.1200/JCO.1997.15.6.2302. J Clin Oncol. 1997. PMID: 9196144 Clinical Trial.
Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.
Levine MN, Bramwell VH, Pritchard KI, Norris BD, Shepherd LE, Abu-Zahra H, Findlay B, Warr D, Bowman D, Myles J, Arnold A, Vandenberg T, MacKenzie R, Robert J, Ottaway J, Burnell M, Williams CK, Tu D. Levine MN, et al. Among authors: shepherd le. J Clin Oncol. 1998 Aug;16(8):2651-8. doi: 10.1200/JCO.1998.16.8.2651. J Clin Oncol. 1998. PMID: 9704715 Clinical Trial.
Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole.
Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Livingston RB, Davidson NE, Perez EA, Chavarri-Guerra Y, Cameron DA, Pritchard KI, Whelan T, Shepherd LE, Tu D. Goss PE, et al. Among authors: shepherd le. Ann Oncol. 2013 Feb;24(2):355-361. doi: 10.1093/annonc/mds330. Epub 2012 Oct 1. Ann Oncol. 2013. PMID: 23028039 Free PMC article. Clinical Trial.
Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials.
Yerushalmi R, Dong B, Chapman JW, Goss PE, Pollak MN, Burnell MJ, Levine MN, Bramwell VHC, Pritchard KI, Whelan TJ, Ingle JN, Shepherd LE, Parulekar WR, Han L, Ding K, Gelmon KA. Yerushalmi R, et al. Among authors: shepherd le. Ann Oncol. 2017 Jul 1;28(7):1560-1568. doi: 10.1093/annonc/mdx152. Ann Oncol. 2017. PMID: 28379421 Free PMC article.
Expression of both estrogen receptor-beta 1 (ER-β1) and its co-regulator steroid receptor RNA activator protein (SRAP) are predictive for benefit from tamoxifen therapy in patients with estrogen receptor-alpha (ER-α)-negative early breast cancer (EBC).
Yan Y, Li X, Blanchard A, Bramwell VH, Pritchard KI, Tu D, Shepherd L, Myal Y, Penner C, Watson PH, Leygue E, Murphy LC. Yan Y, et al. Among authors: shepherd l. Ann Oncol. 2013 Aug;24(8):1986-93. doi: 10.1093/annonc/mdt132. Epub 2013 Apr 11. Ann Oncol. 2013. PMID: 23579816 Free article. Clinical Trial.
Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group.
Baetz T, Belch A, Couban S, Imrie K, Yau J, Myers R, Ding K, Paul N, Shepherd L, Iglesias J, Meyer R, Crump M. Baetz T, et al. Among authors: shepherd l. Ann Oncol. 2003 Dec;14(12):1762-7. doi: 10.1093/annonc/mdg496. Ann Oncol. 2003. PMID: 14630682 Free article. Clinical Trial.
The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L).
Wasan KM, Goss PE, Pritchard PH, Shepherd L, Palmer MJ, Liu S, Tu D, Ingle JN, Heath M, Deangelis D, Perez EA. Wasan KM, et al. Among authors: shepherd l. Ann Oncol. 2005 May;16(5):707-15. doi: 10.1093/annonc/mdi158. Epub 2005 Apr 7. Ann Oncol. 2005. PMID: 15817595 Free article. Clinical Trial.
581 results